Carey K. Anders, MD, concludes with a look toward the future of HER2+ breast cancer treatment and provides advice to community oncologists treating patients with breast cancer.
Trastuzumab-strf Gets FDA Approval in Overexpressing Breast and Gastric Cancers
Patients with overexpressing breast and gastric cancers may now receive trastuzumab-strf, which has been approved by the FDA.
Managing CDK4/6 Inhibitor, ADC Toxicity in Metastatic Breast Cancer
Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.
Pembrolizumab Maintenance Yields Enduring Responses in HER2– Breast Cancer
Further research may validate identified biomarkers and refine patient selection criteria for pembrolizumab therapy in breast cancer.
HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer
Tucatinib plus trastuzumab emtansine shows a progression-free survival improvement in HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, says Sara A. Hurvitz, MD, FACP.
7-Gene Predictive Biosignature Helps Predict Ipsilateral Breast Cancer Recurrence
DCISionRT is a risk-assessment test for patients designed to predict RT benefit and develop their recurrence risk after surgery alone or with radiation.
69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases